AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced it is naming its tendon and ligament portfolio under the new brand AlloConnex™.
CENTENNIAL, Colo., July 23, 2020 /PRNewswire/ -- AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue allografts to help surgeons heal their patients, today announced it is naming its tendon and ligament portfolio under the new brand AlloConnex™. "Over the past 25 years, our offering of tendons and ligaments has grown, and the timing felt right to package this robust product line under a new brand," said Kevin Whitten, Senior Vice President, Marketing and Sales. "AlloConnex aligns with AlloSource's other brands, while conveying the physical connection of tendon and ligament transplantation through the skilled hands of a surgeon." The AlloConnex tendon and ligament portfolio supports a multitude of procedures surgeons perform to connect patients back to their active lifestyles. AlloSource's tendon supply includes single strand, double strand, double bundle and pre-shaped configurations. Specific allografts in the AlloConnex portfolio include the Achilles, anterior tibialis, gracilis, peroneus longus, posterior tibialis and semitendinosus tendons, as well as patellar ligaments. AlloConnex tendons and ligaments are cleansed by AlloSource's AlloTrue™ technology. The patented process is designed to penetrate deep within donor tissue, removing blood and lipids, as well as reducing bioburden. AlloTrue utilizes a combination of treatments including antibiotics and alcohol. The deep cleansing, with minimal tissue manipulation, results in microbial inactivation while maintaining the biomechanical properties of the tendons and ligaments. To learn more about AlloConnex tendons and ligaments, please visit allosource.org/products/alloconnex. About AlloSource Media Contact
SOURCE AlloSource |